InMed Pharmaceuticals Inc. 8-K

What Happened

• InMed Pharmaceuticals Inc. announced in an 8-K (filed June 10, 2026) that Nasdaq notified the company on June 3, 2026 that it had regained compliance with the $1.00 minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq had earlier notified the company on March 27, 2026 that the closing bid was below $1.00 for 30 consecutive trading days during the February 11–March 26, 2026 period. Nasdaq advised the company the matter is now closed. InMed issued a press release on June 4, 2026 announcing the regained compliance.

Key Details

• Nasdaq notice of non-compliance: March 27, 2026 (closing bid below $1.00 from Feb 11–Mar 26, 2026).
• Regained compliance notice: June 3, 2026—closing bid was at or above $1.00 for 10 consecutive business days (May 19–June 2, 2026).
• Company announced compliance publicly via press release on June 4, 2026 (Exhibit 99.1 to the 8-K).
• Nasdaq informed the company the matter is closed—no further action noted in this 8-K.

Why It Matters

• For investors, regaining compliance preserves InMed’s continued listing on The Nasdaq Capital Market, maintaining public trading status and liquidity.
• The filing documents resolution of a prior compliance deficiency; it does not report financial results, management changes, or other corporate actions.